A&O Shearman announced that HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate, is expected to enter clinical trials in H2 2026.

A&O Shearman transforms the way law is practiced, to deliver unparalleled results for our clients' most complex matters – everywhere in the world. We’re a law firm at the forefront of the forces changing the current of global business: energy transition, life sciences, technology, private capital, finance and beyond. Fluent in U.S. law, English law, and the laws of the world’s most dynamic markets in equal measure, we support our clients with bespoke teams of expert minds. Ready to provide unmatched insight and seamless delivery, right now. A firm where everyone can belong, excel, move markets and make a difference. On May 1, 2024, Allen & Overy and Shearman & Sterling merged to become A&O Shearman. Content on this page is general information only and not legal advice. Content may include attorney advertising.